Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Comparison of cardiovascular co-morbidities and CPAP use in patients with positional and non-positional mild obstructive sleep apnea

  • Yi-Chih Huang1,
  • Chun-Yao Lin3,
  • Chou-Chin Lan1, 2,
  • Yao-Kuang Wu1, 2,
  • Chor-Shen Lim1,
  • Chun-Yao Huang1,
  • Hsuan-Li Huang2, 4,
  • Kuan-Hung Yeh2, 4,
  • Yu-Chih Liu3 and
  • Mei-Chen Yang1, 2Email author
BMC Pulmonary Medicine201414:153

https://doi.org/10.1186/1471-2466-14-153

Received: 22 August 2013

Accepted: 23 September 2014

Published: 26 September 2014

Abstract

Background

This retrospective cohort study aimed to determine if there are differences in cardiovascular co-morbidities, blood pressure (BP) and continuous positive airway pressure (CPAP) use between patients with positional-dependent and nonpositional-dependent obstructive sleep apnea (OSA).

Methods

Patients who were referred for overnight polysomnography for suspected OSA between 2007 and 2011 were screened. A total of 371 patients with OSA were included for analysis and divided into six groups according to positional-dependency and severity of OSA: positional mild (n = 52), positional moderate (n = 29), positional severe (n = 24), non-positional mild (n = 18), non-positional moderate (n = 70) and non-positional severe group (n = 178). The six groups were compared for anthropometric and polysomnographic variables, presence of cardiovascular co-morbidities, morning and evening BP and the changes between evening and morning BP, and CPAP device usage patterns.

Results

Demographic and anthropometric variables showed non-positional severe OSA had poor sleep quality and higher morning blood pressures. Positional mild OSA had the lowest cardiovascular co-morbidities. Overall CPAP acceptance was 45.6%. Mild OSA patients had the lowest CPAP acceptance rate (10%), followed by moderate group (37.37%) and severe group (61.88%, P < 0.001). However, the significant difference in CPAP acceptance across OSA severity disappeared when the data was stratified by positional dependency.

Conclusions

This study found that positional mild OSA had less cardiovascular co-morbidities compared with subjects with positional severe OSA. Independent of posture, CPAP acceptance in patients with mild OSA was low, but CPAP compliance was similar in CPAP acceptors regardless of posture dependency of OSA. Since there are increasing evidences of greater cardiovascular risk for untreated mild OSA, improving CPAP acceptance among mild OSA patients may be clinically important regardless of posture dependency.

Keywords

Obstructive sleep apnea Positional sleep apnea Cardiovascular co-morbidities Hypertension Continuous positive airway pressure

Background

Severe obstructive sleep apnea (OSA) is associated with an increased risk of cardiovascular (CV) disease, including coronary artery disease, heart failure, and stroke [1]. Although often overlooked, mild OSA has been associated with a higher prevalence of CV disease and significant CV co-morbidities, including hypertension and carotid artery atherosclerosis [25]; although, other studies have not found an association of OSA with hypertension and CV diseases [6]. As the severity of mild OSA tends to worse over time, active and effective treatment for mild OSA may be required [7].

The vast majority of patients with mild OSA exhibit position-dependent apnea, in which the presence and severity of symptoms are related to body position, and the associated gravitational changes, during sleep [8, 9]. Specifically, gravity pulls the jaw and the tongue downwards while in the supine position, partially or fully obstructing the airway. Positional OSA is generally indicated by a total apnea-hypopnea index (AHI) ≥ 5, with a > 50% reduction in the AHI between the supine and lateral positions, and an AHI that normalizes (AHI < 5) in the lateral position [9].

Various treatment modalities are available for mild OSA. Positional therapy, aimed at maintaining a non-supine sleep position, is often used as first-line treatment for patients with positional mild OSA, but has only moderate efficacy and poor compliance [10]. Continuous positive airway pressure (CPAP) treatment significantly reduces the AHI and improves sleep efficiency in patients with OSA [11]; however both patients with mild OSA and their clinicians are significantly less inclined to accept CPAP treatment [11]. Mandibular advancement devices, while generally preferred by patients over CPAP, are not as effective in reducing sleep apnea symptoms as CPAP [11]. In addition to its proven efficacy for improving apnea symptoms, effective CPAP treatment is associated with significantly decreased risks for cardiovascular disorders, including reduced arterial stiffness and decreased blood pressure (BP) in patients with OSA [1214].

Few studies have examined BP and CPAP use in patients with positional-dependent mild OSA. Therefore, the primary aim of this study was to determine if there are differences in BP (including morning BP, evening BP, and the different in BP between evening and morning) between patients who have positional and non-positional mild OSA. We also evaluated patients with mild, moderate, and severe OSA. CPAP usage patterns in these patients were also evaluated.

Methods

Study subjects

A total of 874 consecutive adult patients (aged ≥ 18 years) were screened in this retrospective cohort study. All were referred to the Chest and Sleep Clinic of Taipei Tzuchi Hospital, the Buddhist Tzuchi Medical Foundation (New Taipei City, Taiwan) for overnight polysomnography (PSG) for suspected OSA between January 2007 and December 2011. None of the subjects were previously diagnosed with OSA. Patients who underwent split-night sleep studies were excluded (n = 46) due to the inherent difficulty in separating the diagnostic and therapeutic portions of the study for postural effects [15]. Patients with PSG results that did not include at least 15 minutes of data obtained in both supine and non-supine positions were also excluded (n = 352) [15]. This time period was chosen with reference to a previous study [15] and did not have to be consecutive. Patients with PSG results indicating non-apnea (AHI < 5/h) were excluded (n = 103). We also excluded two patients whose PSG data was missing. The remaining 371 patients with OSA (AHI ≥ 5) were included in the final analyses. These 371 patients were divided into six groups by positional-dependency of OSA and the severity of OSA. Positional OSA was defined as a > 50% reduction in the AHI between the supine and lateral positions and an AHI that normalized (AHI < 5) in a non-supine sleep position. This study was approved by the Institutional Review Board of the Taipei Tzuchi Hospital, the Buddhist Tzuchi Medical Foundation. The informed patient consent was waived since this was retrospective study.

Measurements

Anthropometric measurements and demographic data

Medical history and anthropometric data were recorded prior to PSG study, and included body weight, height, body mass index (BMI), neck, waist, and hip circumference, waist-to-hip ratio, smoking status, hypertension, anti-hypertensive agents usage, and presence of CV diseases, defined as previous diagnosis of coronary artery disease (CAD) or a history of cerebrovascular accident (CVA).

Sleep parameters

Excessive daytime sleepiness was evaluated using the Chinese version of the Epworth Sleepiness Scale (ESS) before overnight PSG study [16]. An attended, standard overnight PSG study was performed by trained sleep technicians at the sleep center. During PSG, electroencephalography (EEG), electrooculography, chin and bilateral anterior tibialis surface electromyography, electrocardiography, airflow through the nose and mouth (registered by thermistor), thoracoabdominal movements (registered by respiratory inductive plethysmography), position (by a sensor on the respiratory inductive plethysmography), snoring, and oxygen saturation (by pulse oximetry) were recorded. The PSG study lasted for at least 6 hours. PSG data were analyzed by manual scoring for every 30-second epoch by trained sleep technicians and were reviewed by sleep specialists.

Sleep stage was scored by trained sleep technicians using the standard criteria of Rechtschaffen and Kales [17]. An apnea event was defined as an 80-100% reduction in airflow lasting for at least 10 seconds. A hypopnea event was defined as a reduction in airflow of at least 50% for at least 10 seconds or at least a 30% reduction in airflow for at least 10 seconds as compared with baseline and associated with at least 3% oxygen desaturation or with an EEG arousal. AHI was calculated from the total number of apnea and hypopnea events per hour of sleep. The desaturation index (DI) was defined as > 3% oxygen desaturation per hour of sleep. The arousal index (AI) was defined as arousal episodes per hour of sleep [18]. Sleep efficiency was defined as the fraction of total sleep time to total recording time. Sleep latency was defined as the time from lights off to the first identifiable sleep stage. Rapid eye movement (REM) latency was defined as the time from the first identifiable sleep stage to the first REM sleep.

Blood pressure

BP was measured with the patient in the supine position by trained technicians using an automated sphygmomanometer (Welch Allyn Vital Signs Monitor 300 Series) with an optimal cuff. The automated sphygmomanometer was regularly calibrated at least every year by the technician from the manufacturer who calibrated and/or validated the instrument against manual measurement performed with a standard mercury sphygmomanometer. Evening BP was measured after 15 minutes of rest and before sleep onset. Morning BP was measured immediately upon awakening with the patient attached to all PSG equipments. Two consecutive determinations were made on each occasion, separated by 5 minutes, and the results were averaged for both the evening and morning BP readings. Mean arterial blood pressure (MABP) was calculated using the systolic BP (SBP) and diastolic BP (DBP): MABP = 1/3 SBP + 2/3 DBP. Evening-to-morning BP difference was determined by: morning BP – evening BP.

CPAP acceptance and compliance

All patients were offered treatment with CPAP. CPAP acceptance refers to the proportions of patients who meet the selection criteria for CPAP treatment and were willing to try CPAP and actually to use it at home [19, 20]. CPAP compliance refers to the proportions of patients using CPAP and delivering a pre-set level over a given time period [19, 20] Patients were routinely followed up every 3 months at the outpatient clinic. According to the policy of our sleep center, we routinely collected objective CPAP usage data (recorded by the device software) at each visit. The CPAP usage included percentage of days used, percentage of nights during which CPAP was used for ≥ 4 hours, and the overall mean hours used per night.

High CPAP compliance was defined as ≥ 4 hours of CPAP per night for ≥ 70% of the nights [21]. Patients who did not meet these levels of CPAP usage were defined as having low CPAP compliance.

Statistical analysis

Results for continuous variables are presented as mean ± standard deviation, whereas results for categorical variables are presented as number (percentage). A Kolmogorov-Smirnov test was used to test for normality. Baseline characteristics between the positional OSA and non-positional OSA groups were compared by one-way analysis of variance (ANOVA) (continuous variables) or chi-square/Fisher’s exact test (categorical variables). When significant results were revealed by ANOVA, post-hoc tests with Bonferroni correction or Dunnett’s test were then carried out. Daytime sleepiness measurements, overnight polysomnography and blood pressure results among groups adjusting for baseline differences were estimated by linear regression models. All statistical assessments were evaluated at a two-sided alpha level of 0.05 using SAS software, version 9.2 (SAS Institute, Inc., Cary, NC, USA).

Results

Baseline characteristics and anthropometric measurements

The screening results are summarized in Figure 1. A total of 874 adult patients met the inclusion criteria for screening. Of these, 46 were excluded for undergoing split-night studies, 352 for not having sufficient data in both supine and non-supine sleep positions, 103 for having normal AHI, and 2 for missing PSG data.
Figure 1

Flowchart of patient enrollment. PSG: polysomnography; OSA: obstructive sleep apnea; AHI: apnea-hypopnea index.

The 371 patients who were included in the analysis were divided into six groups: non-positional mild OSA (group 1, n = 18), non-positional moderate OSA (group 2, n = 70), non-positional severe OSA (group 3, n = 178), positional mild OSA (group 4, n = 52), positional moderate OSA (group 5, n = 29), and positional severe OSA (group 6, n = 24).

The baseline characteristics of these six groups are summarized in Table 1. Except for age, CAD and CVA, differences in gender, neck circumference, waist circumference and hip circumference, ratio of waist to hip, BMI, smoking history, CV co-morbidities, hypertension and anti-hypertensive drug use among groups were found. There were more males than females in the study with the highest proportion of males having severe OSA in both the non-positional and positional groups. Subjects with severe OSA in the non-positional subgroup had greater waist and hip circumference, higher waist-to-hip ratio, and BMI than the subjects with severe OSA than in the positional group. The neck circumference, waist circumference, and hip circumference in subjects with severe OSA (Group 3) in the non-position cohort were larger compared with those with mild (Group 1) or moderate (Group 2) OSA. There was no difference in these same variables across disease severity in the positional cohort. A similar percentage of patients had hypertension between the non-positional and positional cohort of subjects.
Table 1

Baseline characteristics of patients with non-positional and positional obstructive sleep apnea

 

Non-positional

Positional

P-value

 

G1: Mild

G2: Moderate

G3: Severe

G4: Mild

G5: Moderate

G6: Severe

 

(n = 18)

(n = 70)

(n = 178)

(n = 52)

(n = 29)

(n = 24)

Age, years

61.39 ± 15.27

60.9 ± 13.06

56.39 ± 13.54

56.55 ± 13.2

54.76 ± 10.5

55.46 ± 13.95

0.999

Gender

      

0.011*

Female

6(33.33%)

25(35.71%)

34(19.1%)b

18(34.62%)

6(20.69%)

2(8.33%)a

 

Male

12(66.67%)

45(64.29%)

144(80.9%)

34(65.38%)

23(79.31%)

22(91.67%)

 

Neck circumference, cm

37.83 ± 3.63

38.22 ± 3.05

40.55 ± 3.7a,b

37.28 ± 3.05

38.66 ± 2.79

38.58 ± 2.62

<0.001*

Waist circumference, cm

92.64 ± 10.66

97.24 ± 9.08

103.21 ± 11.67a,b

91.99 ± 10.59

95.71 ± 8.34

92.64 ± 5.51c

<0.001*

Hip circumference, cm

99.36 ± 9.95

103.43 ± 9.31

107.4 ± 10.55a,b

100.73 ± 7.5

102.71 ± 6.69

100.02 ± 4.99c

<0.001*

Waist-to-hip ratio, %

0.93 ± 0.06

0.94 ± 0.05

0.96 ± 0.05

0.91 ± 0.07

0.93 ± 0.05

0.92 ± 0.05c

<0.001*

BMI, kg/m2

26.27 ± 4.78

27.58 ± 4.76

29.98 ± 5.19

26.29 ± 3.41

27.74 ± 2.96

26.15 ± 2.78c

<0.001*

Smoking history

      

0.017*

Past-smoker

4(22.22%)

14(20%)

42(23.6%)

9(17.31%)

6(20.69%)

11(45.83%)a

 

Never smoked

8(44.44%)

46(65.71%)

83(46.63%)

34(65.38%)

17(58.62%)

11(45.83%)

 

Current smoker

6(33.33%)

10(14.29%)

53(29.78%)

9(17.31%)

6(20.69%)

2(8.33%)

 

CV co-morbidities

       

Any CV co-morbidity

11(61.11%)

39(55.71%)

113(63.48%)

19(36.54%)

15(51.72%)

17(70.83%)a

0.018*

HTN

11(61.11%)

38(54.29%)

111(62.36%)

18(34.62%)

15(51.72%)

16(66.67%)a

0.015*

Anti-HTN drugs

11(100%)

37(97.37%)

89(80.18%)b

18(100%)

13(86.67%)

14(87.5%)

0.021*

Dosage of anti-HTN drugs (number of tablets /day)

2.23 ± 1.40

2.21 ± 1.15

1.98 ± 1.14

1.74 ± 1.24

1.35 ± 0.52

1.77 ± 0.92

0.192

CAD

0(0%)

3(4.29%)

13(7.3%)

0(0%)

1(3.45%)

2(8.33%)

0.394

CVA

2(11.11%)

15(21.43%)

32(17.98%)

4(7.69%)

6(20.69%)

5(20.83%)

0.307

BMI: body mass index; CV: cardiovascular; HTN: hypertension; CAD: coronary artery disease; CVA: cerebrovascular accident.

Results are mean ± standard deviation for continuous variables and number (percentage) for categorical variables.

Intergroup comparisons were made by analysis of variance followed by Bonferroni correction or Dunnett’s test for post-hoc test (continuous variables) or Chi-square / Fisher’s exact tests (categorical variables).

*Indicates a significant between group difference, P < 0.05.

Only HTN patients were analyzed.

aIndicates significant difference from the mild subgroup within the nonpositional (or positional) group, p < 0.05.

bIndicates significant difference from the moderate subgroup within the nonpositional (or positional) group, p < 0.05.

cIndicates significant difference between the corresponding subgroups of nonpositional and positional groups, p < 0.05.

Sleep parameters

Table 2 summarizes the daytime sleepiness measurements and the overnight PSG results. ESS scores were not significantly different across groups. After adjusting for gender, waist-to-hip ratio, BMI, smoking and cardiovascular co-morbidity, significant associations were found for AHI, supine AHI, lateral AHI, DI, AI, S1, S2, REM, SaO2 mean, and SaO2 minimal (all P < 0.001). Patients with non-positional severe OSA had higher AHI (55.98 ± 1.01 episodes/hour), supine AHI (66.11 ± 1.16 episodes/hours), lateral AHI (39.29 ± 1.35 episodes/hours) and lower SaO2 mean (90.65% ± 0.24%) than those with positional OSA. Within the non-positional group, group 3 had the largest values of the number of AHI, supine AHI, lateral AHI, DI, AI, and S1, followed by group 2 than group 1 who were similar in respect to the number of lateral AHI, DI, AI, and S1. S2, SaO2 mean, and SaO2 minimal in group 3 were smaller than those in the other two subgroups. In the positional group, the frequency of AHI and supine AHI were different among three subgroups in order of G6 > G5 > G4. The number of DI and AI in both group 4 and group 5 were smaller than those in the group 6. The SaO2 minimal was significantly different only between the group 4 and group 6.
Table 2

Comparison of daytime sleepiness measurements, overnight polysomnography and blood pressure results for patients with non-positional and positional obstructive sleep apnea

 

Non-positional

Positional

Adjusted

 

G1: Mild

G2: Moderate

G3: Severe

G4: Mild

G5: Moderate

G6: Severe

(n = 18)

(n = 70)

(n = 178)

(n = 52)

(n = 29)

(n = 24)

P-value1

Daytime sleepiness measurements

       

  ESS score

11.09 ± 1.31

9.91 ± 0.66

11.06 ± 0.43

9.65 ± 0.8

10.55 ± 1.02

10.24 ± 1.15

0.618

Overnight polysomnography

       

  AHI, episodes/hour

12.68 ± 3.06

24.41 ± 1.55a

55.98 ± 1.01a,b

11.93 ± 1.86

21.97 ± 2.39a

44.41 ± 2.69a,b,c

<0.001*

  Supine AHI, episodes/hour

17.15 ± 3.54

33.98 ± 1.80a

66.11 ± 1.16a,b

18.55 ± 2.13

34.88 ± 2.76a

54.55 ± 3.1a,b,c

<0.001*

  Lateral AHI, episodes/hour

10.26 ± 4.13

14.35 ± 2.10

39.29 ± 1.35a,b

3.73 ± 2.48

2.25 ± 3.22c

5.17 ± 3.62c

<0.001*

  DI, episodes/hour

7.07 ± 3.38

15.12 ± 1.95

45.62 ± 1.27a,b

7.97 ± 2.33

14.90 ± 3.00

35.91 ± 3.37a,b

<0.001*

  AI, episodes/hour

30.87 ± 3.66

36.78 ± 1.86

56.65 ± 1.21a,b

19.50 ± 2.23

27.91 ± 2.86

46.99 ± 3.23a,b

<0.001*

  Sleep efficiency, %

68.83 ± 3.61

74.9 ± 1.84

77.62 ± 1.19

77.16 ± 2.2

78.46 ± 2.82

78.48 ± 3.18

0.224

  Sleep latency, minute

28.85 ± 7.06

27.53 ± 3.59

22.3 ± 2.33

23.64 ± 4.3

16.58 ± 5.52

24.6 ± 6.22

0.601

  REM latency, minute

120.2 ± 17.1

134.32 ± 8.83

141.17 ± 5.7

113.89 ± 10.29

126.42 ± 12.99

147.72 ± 15.25

0.238

  S1, %

22.22 ± 3.18

24.01 ± 1.62

36.19 ± 1.05a,b

20.33 ± 1.94

23.30 ± 2.49

28.61 ± 2.8

<0.001*

  S2, %

62.00 ± 3.16

60.83 ± 1.60

51.52 ± 1.04a,b

60.52 ± 1.92

59.14 ± 2.47

57.84 ± 2.78

<0.001*

  S34, %

3.18 ± 1.35

2.72 ± 0.69

2.5 ± 0.44

4.01 ± 0.82

4.13 ± 1.06

2.61 ± 1.19

0.560

  REM, %

12.60 ± 1.54

12.43 ± 0.78

9.78 ± 0.51

15.14 ± 0.94

13.43 ± 1.20

10.94 ± 1.35

<0.001*

  SaO2 mean, %

92.92 ± 0.73

93.23 ± 0.37

90.65 ± 0.24b

93.91 ± 0.45

94.14 ± 0.57

93.66 ± 0.65c

<0.001*

  SaO2 minimal, %

86.36 ± 1.90

81.22 ± 0.97a

76.02 ± 0.63a,b

84.56 ± 1.17

81.87 ± 1.49

76.96 ± 1.67a

<0.001*

Blood pressure

       

  Evening SBP, mmHg

125.28 ± 3.43

127.46 ± 1.74

129.23 ± 1.13

124.02 ± 2.09

123.05 ± 2.68

126.01 ± 3.02

0.176

  Evening DBP, mmHg

76.84 ± 2.49

77.15 ± 1.27

79.29 ± 0.82

76.47 ± 1.52

73.78 ± 1.95

78.76 ± 2.19

0.138

  Evening MABP, mmHg

92.99 ± 2.61

93.92 ± 1.33

95.93 ± 0.86

92.32 ± 1.59

90.2 ± 2.04

94.51 ± 2.3

0.119

  Morning SBP, mmHg

125.91 ± 3.27

126.83 ± 1.66

132.44 ± 1.08

125.06 ± 1.99

122.72 ± 2.56

126.56 ± 2.88

0.002*

  Morning DBP, mmHg

78.37 ± 2.83

79.62 ± 1.44

83.74 ± 0.93b

79.06 ± 1.72

77.32 ± 2.21

80.81 ± 2.49

0.033*

  Morning MABP, mmHg

94.23 ± 2.79

95.35 ± 1.42

99.97 ± 0.92

94.39 ± 1.70

92.47 ± 2.18

96.07 ± 2.46

0.006*

  Evening-to-morning SBP difference, mmHg

0.63 ± 2.67

-0.63 ± 1.36

3.21 ± 0.88

1.04 ± 1.63

-0.33 ± 2.09

0.54 ± 2.36

0.234

  Evening-to-morning DBP difference, mmHg

1.53 ± 2.15

2.47 ± 1.09

4.45 ± 0.71

2.59 ± 1.31

3.54 ± 1.68

2.05 ± 1.89

0.526

  Evening-to-morning MABP difference, mmHg

1.23 ± 2.11

1.43 ± 1.07

4.04 ± 0.7

2.07 ± 1.28

2.26 ± 1.65

1.55 ± 1.86

0.338

ESS: Epworth Sleepiness Scale; AHI: apnea-hypopnea index; DI: desaturation index; AI: arousal index; REM: rapid eye movement; SaO2: oxygen saturation; SBP: systolic blood pressure; DBP: diastolic blood pressure; MABP: mean arterial blood pressure.

Results are estimated mean ± standard deviation.

*Indicates a significant association, P < 0.05.

1After adjusting for gender, ratio of waist to hip, BMI, smoking, and cardiovascular comorbidity, associations between factors and groups were assessed by linear regression and P-values were estimated using Wald’s test. Post-hoc testes were examined by Boferroni correction.

aIndicates significant difference from the mild subgroup within the nonpositional (or positional) group, p < 0.05.

bIndicates significant difference from the moderate subgroup within the nonpositional (or positional) group, p < 0.05.

cIndicates significant difference between the corresponding subgroups of nonpositional and positional group, p < 0.05.

Blood pressure

As shown in Table 2, morning BP differed across all groups (P = 0.002 for morning SBP, P =0.033 for morning DBP, P = 0.006 for morning MABP). BP was similar between non-positional and positional group; however, the morning DBP in the group 2 was lower compared with group 3.

CPAP acceptance and compliance

Table 3 shows CPAP acceptance and compliance. Mild OSA patients showed the lowest CPAP acceptance rate (10%), followed by moderate group (37.37%) and severe group (61.88%, P < 0.001). However, the significant difference in CPAP acceptance across OSA severity disappeared when the data was stratified by positional dependency. The duration of follow-up varied across groups ranging from 15.5 to 47 months.
Table 3

Continuous positive airway pressure acceptance and compliance among patients with non-positional and positional obstructive sleep apnea

Outcome

Mild

Moderate

Severe

P-value for comparison among severity levels

Non-positional

Positional

Non-positional

Positional

Non-positional

Positional

(n = 18)

(n = 52)

(n = 70)

(n = 29)

(n = 178)

(n = 24)

CPAP acceptance by severity

7 (10.00%)

37 (37.37%)

125 (61.88%)

<0.001*

CPAP acceptance in each group

1 (5.56%)

6 (11.54%)

26 (37.14%)

11 (37.93%)

110 (61.80%)

15 (62.50%)

 

CPAP compliance1

      

0.896

  High

1 (100%)

4 (66.67%)

18 (69.23%)

7 (63.64%)

79 (71.81%)

11 (73.33%)

 

  Low

0 (0%)

2 (33.33%)

8 (30.77%)

4 (36.36%)

31 (28.19%)

4 (26.67%)

 

Follow-up duration, months1

47.00

15.50 ± 9.57

20.62 ± 15.58

23.09 ± 19.54

22.27 ± 15.58

17.07 ± 14.68

NA

CPAP: continuous positive airway pressure, NA: not available due to only one case in one group.

Results are number (percentage) for categorical variables and mean ± standard deviation for continuous variables. Chi-square test or Fisher’s exact test was implemented for categorical variables.

1Statistics were derived from CPAP acceptors.

Discussion

This study found that positional mild OSA had less CV co-morbidities and non-positional moderate group had lower morning BP compared with severe OSA. In addition, OSA showed varying associations with sleep parameters depending upon severity and positional dependence. Patients with mild OSA had low CPAP acceptance but similar CPAP compliance compared with patients who had moderate or severe OSA. CPAP acceptance was not dependent on posture dependency of OSA.

The prevalence of positional OSA in our study among patients with mild OSA was 74.3% (52 of 70 mild OSA patients). This percentage is similar to that reported in a previous study using the same definitions for positional-dependency [22]. Results of overnight PSG studies showed that patients with mild OSA in the positional group had lower AI and better sleep efficiency than the patients with mild OSA in the non-positional group, which also supports the results of a previous study [8]. AI was within normal limits for our positional mild OSA group, but was higher than normal in the non-positional mild OSA group. Sleep efficiency was lower than normal in both groups. While associations between OSA and hypertension have been generally accepted, studies have also shown that sleep-disordered breathing, short sleep, and poor sleep have been associated with hypertension in the general population [2325]. Therefore, patients experiencing poor sleep quality should receive optimal treatment (including surgery or CPAP), regardless of OSA severity or positional dependency in order to reduce the risk of developing hypertension.

The prevalence of hypertension in both mild OSA groups (61.1% of non-positional mild OSA and 34.6% of positional mild OSA patients) was similar to that reported in a previous study [22] and was higher in both groups than the prevalence in general population [26]. Much evidence supports elevated BP as a predictor of CV disease. Both increased SBP and increased DBP have been reported to be significant predictors of stroke and coronary artery disease [27]. On average, SBP and DBP readings in the morning are 10%-20% lower than BP readings in the evening [28]. A recent study showed that when this morning dip is replaced by a morning surge in patients with hypertension, the risk of developing a major CV event rises significantly [29]. Ting et al. reported that elevated morning SBP was associated with significantly greater respiratory disturbances, blood glucose, and metabolic syndrome score [30]. Many patients with OSA exhibit loss of the overnight dip in BP and exhibit morning BP elevations, possibly due to sympathetic nervous system over activity [31, 32]. In this study, patients in both the positional and non-positional groups showed a loss of evening to morning dip in BP, which supports the aforementioned findings. Our finding suggests that patients with positional mild OSA may have the same level of risk of developing CV disease as patients with non-positional mild OSA. These results suggest that there may be benefit in treating patients with mild OSA regardless of positional dependency. Well-designed randomized controlled trials are needed to directly further address these issues.

Several studies have documented that poor sleep quality is closely associated with hypertension [2325]. There was no evidence that improving sleep lowers blood pressure, until recently. Huang et al. [33] found that the blood pressure of poor sleepers was significantly reduced compared to pretreatment values following zolpidem (a non-benzodiazepine, non-hypotensive mild sedative with a short elimination half-life of 2.5 hrs) treatment (P < 0.05) and more poor sleepers treated with zolpidem were converted from nondipping hypertension to dipping hypertension. Zolpidem treatment did not affect the blood pressure of good sleepers. Additional randomized controlled studies as necessary to further explore the potential that improving sleep, possibly through the use of CPAP, can reduce blood pressure.

Positional therapy is often relied upon as the primary treatment modality for positional mild OSA. A variety of strategies have been proposed for keeping patients in a non-supine position, including the use of tennis balls, vibrating positional alarms, and wearable devices [34, 35]. However, while positional therapy can moderately reduce AHI in some patients, long-term compliance with positional therapy is poor as outlined in recent reviews [10, 36]. In addition, since CPAP clearly provides superior improvement over positional therapy, positional therapy is not recommended for first-line treatment of OSA [10].

The efficacy of CPAP in reducing apnea symptoms and the risk of CV disorders has been clearly demonstrated, making it the treatment of choice for patients with OSA; however, patients are often reluctant to accept CPAP treatment due to perceived inconvenience and discomfort [37]. Unsurprisingly, few patients in our study were willing to start CPAP treatment, especially in the mild OSA patients (10%). However, the overall CPAP acceptance of all the patients was 45.6%, and for patients with mild OSA was 10%. The low acceptance rate may, in part reflect the small sample size and the fact that in Taiwan, the cost of CPAP is not covered by national or commercial insurance and is paid out-of-pocket by the patient and is 2–3 times higher than that in other countries [38]. Acceptance rates from other studies range from 40-90% [3845]. In the studies in which the acceptance rate is higher (about 70%), often CPAP is free to subject participating in these trials [4245]. Other reasons that may have affected the acceptance rate are that the retrospective study design is closer to the real-world setting and that the strong national health insurance and healthcare in Taiwan is so convenient and inexpensive that the Taiwanese pay little attention on health maintenance. Overall CPAP compliance of our patients was 71.4% (120 out of 168 patients) and is comparable with that found in studies in Europe and US which were about 75% and 46%, respectively [42, 43, 4649]. Reasons for the wide range of compliance across countries include different definition of compliance and different sources of CPAP. Moreover, free CPAP in prospective studies results in higher compliance, while out-of-pocket CPAP in retrospective studies results in lower compliance. Nonetheless, the majority of our patients who accepted CPAP treatment showed a high level of compliance. Thus, educational support and physician involvement to increase patient awareness of the increased CV risks, even with mild OSA, and the potential benefits of CPAP treatment for CV health might improve patient acceptance and compliance [41].

There is growing evidence supporting the use of CPAP in sleepy patients with mild OSA [50], however, the findings are mixed and CPAP treatment of mild OSA is recommended as only a treatment option [51]. Given the findings that there is an association of mild OSA with hypertension and mild OSA tends to worse over time, we suggest that CPAP treatment may benefit these patients. However, further randomized controlled studies are required to better understand the potential benefit of CPAP in treating mild OSA and hypertension.

This study is limited by the retrospective design and the small number of patients included. Larger controlled studies are warranted to further study the effects of positional dependency on BP, and CPAP efficacy and usage patterns in patients with OSA. Besides, we used a thermistor (not nasal pressure transducer to detect airflow and not an esophageal pressure sensor to detect respiratory effort related arousal). These may result in an under-estimation of the severity of OSA and consequently misclassification of some patients in the mild and moderate OSA groups.

Conclusion

This study found that positional mild OSA had less cardiovascular co-morbidities and non-positional moderate OSA had lower morning blood pressure compared with severe group. CPAP acceptance by patients with mild OSA was low, but CPAP compliance was similar to that of patients with moderate or severe OSA. CPAP acceptance rate was independent of posture dependency of OSA. Since there is increasing evidences of greater cardiovascular risk for untreated mild OSA, optimal treatment (including CPAP or surgery) for mild OSA regardless of posture dependency is critical. Strategies to improving CPAP acceptance among mild OSA patients will be the issue in the future.

Abbreviations

OSA: 

Obstructive sleep apnea

CPAP: 

Continuous positive airway pressure

CV: 

Cardiovascular

PSG: 

Polysomnography

AHI: 

Apnea-hypopnea index

BP: 

Blood pressure

ESS: 

Epworth sleepiness scale

EEG: 

Electroencephalography

SBP: 

Systolic BP

DBP: 

Diastolic BP

MABP: 

Mean arterial blood pressure

BMI: 

body mass index

CAD: 

Coronary artery disease

CVA: 

Cerebrovascular accident

DI: 

Desaturation index

AI: 

Arousal index

REM: 

Rapid eye movement

SaO2: 

Oxygen saturation.

Declarations

Authors’ Affiliations

(1)
Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Tzuchi Hospital, the Buddhist Tzuchi Medical Foundation
(2)
School of Medicine, Tzu-Chi University
(3)
Divisions of Pulmonary, Critical Care and Sleep Medicine, Chang Gung Memorial Hospital at Keelung
(4)
Division of Cardiology, Department of Internal Medicine, Taipei Tzuchi Hospital, the Buddhist Tzuchi Medical Foundation

References

  1. Thomas JJ, Ren J: Obstructive sleep apnea and cardiovascular complications: perception versus knowledge. Clin Exp Pharmacol Physiol. 2012, 39 (12): 995-1003. 10.1111/1440-1681.12024.View ArticlePubMedGoogle Scholar
  2. Peppard PE, Young T, Palta M, Skatrud J: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000, 342: 1378-1384. 10.1056/NEJM200005113421901.View ArticlePubMedGoogle Scholar
  3. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Loranzi-Filho G: Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2005, 172: 613-618. 10.1164/rccm.200503-340OC.View ArticlePubMedGoogle Scholar
  4. Shahar E, Whitney CW, Redlines S, Lee ET, Newman AB, Nieto FJ, O’connor GT, Boland LL, Schwartz JE, Samet JM: Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001, 163: 19-25. 10.1164/ajrccm.163.1.2001008.View ArticlePubMedGoogle Scholar
  5. Jaimchariyatam N, Rodriguez CL, Budur K: Does CPAP treatment in mild obstructive sleep apnea affect blood pressure?. Sleep Med. 2010, 11: 837-842. 10.1016/j.sleep.2010.05.005.View ArticlePubMedGoogle Scholar
  6. Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, Martínez-Alonso M, Carmona C, Barceló A, Chiner E, Masa JF, Gonzalez M, Marín JM, Garcia-Rio F, Diaz de Atauri J, Terán J, Mayos M, de la Peña M, Monasterio C, del Campo F, Montserrat JM, Spanish Sleep And Breathing Network: Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA. 2012, 307 (20): 2161-2168.View ArticlePubMedGoogle Scholar
  7. Sahlman J, Pukkila M, Seppa J, Tuomilehto H: Evolution of mild obstructive sleep apnea after different treatments. Laryngoscope. 2007, 117: 1107-1111. 10.1097/MLG.0b013e3180514d08.View ArticlePubMedGoogle Scholar
  8. Oksenberg A, Silverberg DS, Arons E, Radwan H: Positional vs nonpositional obstructive sleep apnea patients: anthropomorphic, nocturnal polysomnographic, and multiple sleep latency test data. Chest. 1997, 112: 629-639. 10.1378/chest.112.3.629.View ArticlePubMedGoogle Scholar
  9. Isono S, Tanaka A, Nishino T: Lateral position decreases collapsibility of the passive pharynx in patients with obstructive sleep apnea. Anesthesiology. 2002, 97: 780-785. 10.1097/00000542-200210000-00006.View ArticlePubMedGoogle Scholar
  10. Randerath WJ, Verbraecken J, Andreas S, Bettega G, Boudewyns A, Hamans E, Jalbert F, Paoli JR, Sanner B, Smith I, Stuck BA, Lacassagne L, Marklund M, Maurer JT, Pepin JL, Valipour A, Verse T, Fietze I, European Respiratory Society task force on non-CPAP therapies in sleep apnoea: Non-CPAP therapies in obstructive sleep apnoea. Eur Respir J. 2011, 37: 1000-1028. 10.1183/09031936.00099710.View ArticlePubMedGoogle Scholar
  11. Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ: Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2006, 3: CD001106-PubMedGoogle Scholar
  12. Budhiraja R, Budhiraja P, Quan SF: Sleep-disordered breathing and cardiovascular disorders. Respir Care. 2010, 55: 1322-1332.PubMedPubMed CentralGoogle Scholar
  13. Buchner NJ, Quack I, Stegbauer J, Woznowski M, Kaufmann A, Rump LC: Treatment of obstructive sleep apnea reduces arterial stiffness. Sleep Breath. 2012, 16: 123-133. 10.1007/s11325-010-0465-x.View ArticlePubMedGoogle Scholar
  14. Drager LF, Pedrosa RP, Diniz PM, Diegues-Silva L, Marcondes B, Couto RB, Giorgi DM, Krieger EM, Lorenzi-Filho G: The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea. Hypertension. 2011, 57: 549-555. 10.1161/HYPERTENSIONAHA.110.165969.View ArticlePubMedGoogle Scholar
  15. Mador MJ, Kufel TJ, Magalang UJ, Rajesh SK, Watwe V, Grant BJ: Prevalence of positional sleep apnea in patients undergoing polysomnography. Chest. 2005, 128: 2130-2137. 10.1378/chest.128.4.2130.View ArticlePubMedGoogle Scholar
  16. Chen NH, Johns MW, Li HY, Chu CC, Liang SC, Shu YH, Chuang ML, Wang PC: Validation of a Chinese version of the Epworth sleepiness scale. Qual Life Res. 2002, 11: 817-821. 10.1023/A:1020818417949.View ArticlePubMedGoogle Scholar
  17. Rechtschaffen A, Kales A: A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. 1968, Bethesda: National Institutes of HealthGoogle Scholar
  18. Boselli M, Parrino L, Smerieri A, Terzano MG: Effect of age on EEG arousals in normal sleep. Sleep. 1998, 21: 351-357.PubMedGoogle Scholar
  19. Anstead M, Phillips B, Buch K: Tolerance and intolerance to continuous positive airway pressure. Curr Opin Pulm Med. 1998, 4: 351-354. 10.1097/00063198-199811000-00008.View ArticlePubMedGoogle Scholar
  20. Grunstein RR: Sleep-related breathing disorders. 5. Nasal continuous positive airway pressure treatment for obstructive sleep apnoea. Thorax. 1995, 50 (10): 1106-1113. 10.1136/thx.50.10.1106.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Gay P, Weaver T, Loube D, Iber C, Positive Airway Pressure Task Force; Standards of Practice Committee; American Academy of Sleep Medicine: Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. Sleep. 2006, 29: 381-401.PubMedGoogle Scholar
  22. Mo JH, Lee CH, Rhee CS, Yoon IY, Kim JW: Positional dependency in Asian patients with obstructive sleep apnea and its implication for hypertension. Arch Otolaryngol Head Neck Surg. 2011, 137 (8): 786-790. 10.1001/archoto.2011.122.View ArticlePubMedGoogle Scholar
  23. Bansil P, Kuklina EV, Merritt RK, Yoon PW: Associations between sleep disorders, sleep duration, quality of sleep, and hypertension: results from the National Health and Nutrition Examination Survey, 2005 to 2008. J Clin Hypertens (Greenwich). 2011, 13: 739-743. 10.1111/j.1751-7176.2011.00500.x.View ArticleGoogle Scholar
  24. Gangwisch JE, Heymsfield SB, Boden-Albala B, Buijs RM, Kreier F, Pickering TG, Rundle AG, Zammit GK, Malaspina D: Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension. 2006, 47: 833-839. 10.1161/01.HYP.0000217362.34748.e0.View ArticlePubMedGoogle Scholar
  25. Pepin JL, Borel AL, Tamisier R, Baguet JP, Levy P, Dauvilliers Y: Hypertension and sleep: Overview of a tight relationship. Sleep Med Rev. 2014, doi:10.1016/j.smrv.2014.03.003Google Scholar
  26. Hajjar I, Kotchen JM, Kotchen TA: Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health. 2006, 27: 465-490. 10.1146/annurev.publhealth.27.021405.102132.View ArticlePubMedGoogle Scholar
  27. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T, American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology; American Heart Association Stroke Council; American Heart Association Council on Cardiovascular Nursing; American College of Cardiology Foundation: Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008, 118: 1080-1111. 10.1161/CIRCULATIONAHA.107.189420.View ArticlePubMedGoogle Scholar
  28. Kanbay M, Turgut F, Uyar ME, Akcay A, Covic A: Causes and mechanisms of nondipping hypertension. Clin Exp Hypertens. 2008, 30: 585-597. 10.1080/10641960802251974.View ArticlePubMedGoogle Scholar
  29. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, Ambrosio G, Reboldi G: Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension. 2012, 60: 34-42. 10.1161/HYPERTENSIONAHA.112.191858.View ArticlePubMedGoogle Scholar
  30. Ting H, Lo HS, Chang SY, Chung AH, Kuan PC, Yuan SC, Huang CN, Lee SD: Post- to pre-overnight sleep systolic blood pressures are associated with sleep respiratory disturbance, pro-inflammatory state and metabolic situation in patients with sleep-disordered breathing. Sleep Med. 2009, 10: 720-725. 10.1016/j.sleep.2008.07.010.View ArticlePubMedGoogle Scholar
  31. Dopp JM, Reichmuth KJ, Morgan BJ: Obstructive sleep apnea and hypertension: mechanisms, evaluation, and management. Curr Hypertens Rep. 2007, 9: 529-534. 10.1007/s11906-007-0095-2.View ArticlePubMedGoogle Scholar
  32. Hoffstein V, Mateika J: Evening-to-morning blood pressure variations in snoring patients with and without obstructive sleep apnea. Chest. 1992, 101: 379-384. 10.1378/chest.101.2.379.View ArticlePubMedGoogle Scholar
  33. Huang Y, Mai W, Cai X, Hu Y, Song Y, Qiu R, Wu Y, Kuang J: The effect of zolpidem on sleep quality, stress status, and nondipping hypertension. Sleep Med. 2012, 13 (3): 263-268. 10.1016/j.sleep.2011.07.016.View ArticlePubMedGoogle Scholar
  34. van Maanen JP, Meester KA, Dun LN, Koutsourelakis I, Witte BI, Laman DM, Hilgevoord AA, de Vries N: The sleep position trainer: a new treatment for positional obstructive sleep apnoea. Sleep Breath. 2013, 17: 771-779. 10.1007/s11325-012-0764-5.View ArticlePubMedGoogle Scholar
  35. Bignold JJ, Deans-Costi G, Goldsworthy MR, Robertson CA, McEvoy D, Catcheside PG, Mercer JD: Poor long-term patient compliance with the tennis ball technique for treating positional obstructive sleep apnea. J Clin Sleep Med. 2009, 5: 428-430.PubMedPubMed CentralGoogle Scholar
  36. Smith I, Nadig V, Lasserson TJ: Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009, 2: CD007736-doi:10.1002/14651858.CD007736PubMedGoogle Scholar
  37. Mannarino MR, Di Filippo F, Pirro M: Obstructive sleep apnea syndrome. Eur J Intern Med. 2012, 23: 586-593. 10.1016/j.ejim.2012.05.013.View ArticlePubMedGoogle Scholar
  38. Simon-Tuval T, Reuveni H, Greenberg-Dotan S, Oksenberg A, Tal A, Tarasiuk A: Low socioeconomic status is a risk factor for CPAP acceptance among adult OSAS patients requiring treatment. Sleep. 2009, 32 (4): 545-552.PubMedPubMed CentralGoogle Scholar
  39. Engleman HM, Martin SE, Deary IJ, Douglas NJ: Effect of CPAP therapy on daytime function in patients with mild sleep apnoea/hypopnoea syndrome. Thorax. 1997, 52 (2): 114-119. 10.1136/thx.52.2.114.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Engleman HM, Kingshott RN, Wraith PK, Mackay TW, Deary IJ, Douglas NJ: Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep Apnea/Hypopnea syndrome. Am J Respir Crit Care Med. 1999, 159 (2): 461-467. 10.1164/ajrccm.159.2.9803121.View ArticlePubMedGoogle Scholar
  41. Tarasiuk A, Reznor G, Greenberg-Dotan S, Reuveni H: Financial incentive increases CPAP acceptance in patients from low socioeconomic background. PLoS One. 2012, 7 (3): e33178-10.1371/journal.pone.0033178.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Abdelghani A, Slama S, Hayouni A, Harrabi I, Mezghanni S, Garrouche A, Klabi N, Benzarti M, Jerray M: Acceptance and long-term compliance to continuous positive airway pressure in obstructive sleep apnea. A prospective study on 72 patients treated between 2004 and 2007 [Article in French]. Rev Pneumol Clin. 2009, 65 (3): 147-152. 10.1016/j.pneumo.2009.03.010.View ArticlePubMedGoogle Scholar
  43. Richard W, Venker J, den Herder C, Kox D, van den Berg B, Laman M, van Tinteren H, de Vries N: Acceptance and long-term compliance of nCPAP in obstructive sleep apnea. Eur Arch Otorhinolaryngol. 2007, 264 (9): 1081-1086. 10.1007/s00405-007-0311-3.View ArticlePubMedGoogle Scholar
  44. Gordon P, Sanders MH: Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome. Thorax. 2005, 60 (1): 68-75. 10.1136/thx.2003.007195.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Reeves-Hoche MK, Meck R, Zwillich CW: Nasal CPAP: an objective evaluation of patient compliance. Am J Respir Crit Care Med. 1994, 149 (1): 149-154. 10.1164/ajrccm.149.1.8111574.View ArticlePubMedGoogle Scholar
  46. Collard P, Pieters T, Aubert G, Delguste P, Rodenstein DO: Compliance with nasal CPAP in obstructive sleep apnea patients. Sleep Med Rev. 1997, 1 (1): 33-44. 10.1016/S1087-0792(97)90004-6.View ArticlePubMedGoogle Scholar
  47. Kakkar RK, Berry RB: Positive airway pressure treatment for obstructive sleep apnea. Chest. 2007, 132 (3): 1057-1072. 10.1378/chest.06-2432.View ArticlePubMedGoogle Scholar
  48. Boyacı H, Gacar K, Barış SA, Başyiğit I, Yıldız F: Positive airway pressure device compliance of the patients with obstructive sleep apnea syndrome. Adv Clin Exp Med. 2013, 22 (6): 809-815.PubMedGoogle Scholar
  49. Pieters T, Collard P, Aubert G, Dury M, Delguste P, Rodenstein DO: Acceptance and long-term compliance with nCPAP in patients with obstructive sleep apnoea syndrome. Eur Respir J. 1996, 9 (5): 939-944. 10.1183/09031936.96.09050939.View ArticlePubMedGoogle Scholar
  50. Peker Y: Growing research evidence for continuous positive airway pressure treatment for sleepy patients with milder obstructive sleep apnea. Am J Respir Crit Care Med. 2012, 186 (7): 583-584. 10.1164/rccm.201208-1400ED.View ArticlePubMedGoogle Scholar
  51. Kushida CA, Littner MR, Hirshkowitz M, Morgenthaler TI, Alessi CA, Bailey D, Boehlecke B, Brown TM, Coleman J, Friedman L, Kapen S, Kapur VK, Kramer M, Lee-Chiong T, Owens J, Pancer JP, Swick TJ, Wise MS, American Academy of Sleep Medicine: Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep. 2006, 29 (3): 375-380.PubMedGoogle Scholar
  52. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/14/153/prepub

Copyright

© Huang et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Advertisement